普拉克索 (Mirapex, Mirapexin, Sifrol +2)

概览

Pramipexole is a non-ergot dopamine agonist used to treat the signs and symptoms of idiopathic Parkinson's disease and Restless Legs Syndrome (RLS). It is a dopamine D3-preferring D3/D2 agonist with demonstrated antidepressant effect: the independent PRIME-PRAXOL trial (Nature Medicine, 2026) showed pramipexole significantly reduced anhedonia versus placebo in adults with major depressive disorder, dysthymia, or bipolar depression (SHAPS mean difference −4.04; p=0.006).

作用机制

The exact mechanism of action of pramipexole as a treatment for Parkinson's disease is unknown at this time. It is thought, however, that the ability of pramipexole to cause stimulation of the dopamine receptors in the striatum of the brain, a region that receives a vast array of neurological input and is responsible for a wide variety of functions, may be involved. Studies performed in animals show that pramipexole influences striatal neuronal transmission rates following activation of dopamine receptors . Pramipexole is considered a non-ergot dopamine agonist that shows specificity and strong activity at the D2 subfamily of dopamine receptors in vitro, binding selectively and dopamine D2 receptors and showing a preference for the dopamine D3 receptor subtype rather than other subtypes . The clinical significance of this binding specificity is unknown , .

适应症

This drug is indicated for the symptomatic treatment of Parkinson’s disease . This drug can be administered as monotherapy or in conjunction with levodopa. It is also indicated for symptomatic treatment of moderate to severe primary Restless Legs Syndrome (RLS) .

• Moderate restless legs syndrome (RLS)
• Parkinson's Disease (PD)
• Severe restless legs syndrome (RLS)
• Major depressive disorder (MDD)